Margaret Boltja, MD
Interventional Pain Medicine · Macon, GANPI 1184671133
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,227 of the $7,167 with a category attached, or 86.9%. 37 manufacturers reported payments, led by Nevro Corp. at 32.3% of the total. Reporting peaked in 2021 at $2,134 and has fallen 76.0% since, to $512 in 2025.
Across 209 payments — averaging $34.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$2K
- Abbott$950
- SPR Therapeutics, Inc$530
- Collegium Pharmaceutical, Inc.$407
- Si-bone, Inc.$318
- Curonix LLC$295
- plus $2K from 31 others
What the payments were for
- Travel & lodging$90513%
- Food & beverage$6,22787%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 61 | $2,318 |
| Abbott | 23 | $950 |
| SPR Therapeutics, Inc | 6 | $530 |
| Collegium Pharmaceutical, Inc. | 26 | $407 |
| Si-bone, Inc. | 3 | $318 |
| Curonix LLC | 3 | $295 |
| EMD Serono, Inc. | 4 | $253 |
| Boston Scientific | 5 | $215 |
| Saluda Medical Americas, Inc. | 1 | $194 |
| Medtronic | 6 | $191 |
| MML US, Inc. | 2 | $159 |
| Biogen | 7 | $149 |
| Lilly USA, LLC | 8 | $127 |
| Pfizer | 8 | $122 |
| AstraZeneca | 1 | $106 |
| Indivior Inc. | 4 | $92 |
| Amgen | 5 | $91 |
| Biotronik NRO, Inc. | 3 | $83 |
| Vertos Medical, Inc. | 4 | $74 |
| AbbVie | 5 | $68 |
| GRT US Holding, Inc. | 1 | $60 |
| Scilex Pharmaceuticals Inc. | 4 | $56 |
| Globus Medical | 2 | $36 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Sanofi | 2 | $35 |
| Almatica Pharma LLC | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Argenx US, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Zimmer Biomet | 1 | $11 |
| Foundation Fusion Solutions, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$1,139
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$273
- Senza$247
- Proclaim DRG IPG$200
- Evoke$194
- PROCLAIM$153
- SPRINT PNS System$135
- ReActiv8$130
- Proclaim IPG$129
- Mavenclad$125
- GENERAL PAIN MANAGEMENT$104
How this compares
$7,167 in reported general payments places this provider in the 65th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,505 |
| Gabapentin | 39 | $442 |
| Pregabalin | 22 | $362 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $332 |
| Tramadol Hcl | 11 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $35 | $1,50511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Macon
- Sandeep DattaMacon$28K
- Stephen TaforMacon$16K
- Jeremy PrineMacon$7K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.